Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study

Abstract Introduction This study aimed to retrospectively examine the drug survival of tumor necrosis factor (TNF)-alpha inhibitors and switched subsequent biologic agents after discontinuation of TNF inhibitors. Methods This real-world setting study was conducted at a single academic center. We inc...

Full description

Bibliographic Details
Main Authors: Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Makiko Mieno, Mamitaro Ohtsuki
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Dermatology and Therapy
Subjects:
Adalimumab
Biologics
Certolizumab pegol
Drug switching
Infliximab
Kaplan–Meier survival curves
Online Access:https://doi.org/10.1007/s13555-023-00932-0

Internet

https://doi.org/10.1007/s13555-023-00932-0

Similar Items